FDA Approves Niraparib-abiraterone Acetate Combo for CSPC



The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/fda-approves-niraparib-abiraterone-acetate-combo-cspc-2025a1000z65?src=rss

Author :

Publish date : 2025-12-15 18:14:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version